Management Strategies for Patients with Non-Infectious Cystitis: A Review of the Literature.
Bladder pain syndrome
Chronic pelvic pain syndrome
Interstitial cystitis
Management
Noninfectious cystitis
Therapies
Journal
Current urology reports
ISSN: 1534-6285
Titre abrégé: Curr Urol Rep
Pays: United States
ID NLM: 100900943
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
accepted:
15
08
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
epublish
Résumé
The management of noninfectious cystitis continues to evolve as new treatments continue to be developed and investigated. This review aims to synthesize the most recent data regarding management strategies for noninfectious cystitis focused on non-ulcerative, ulcerative, eosinophilic, and ketamine-induced cystitis. Several novel treatments have shown promise as management options including combination antihistamine therapy, phosphodiesterase 5 inhibitors, alpha lipoic acid supplements, and onabotulinumtoxin A. Recent studies have also found pentosan polysulfate sodium to have adverse ophthalmologic effects. For patients with ulcerative cystitis, recent research has shown that fulguration with or without triamcinolone injections should not be delayed. The treatment of noninfectious cystitis should be patient specific based on factors including etiology and symptom profile. Multimodal regimens are often the most effective. Treatment should be started with conservative options and escalated as necessary to oral treatments, intravesical options, or procedural management.
Identifiants
pubmed: 39347847
doi: 10.1007/s11934-024-01236-2
pii: 10.1007/s11934-024-01236-2
doi:
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Ketamine
690G0D6V8H
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Clemens JQ, Erickson DR, Varela NP, Lai HH. Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome. J Urol. 2022;208(1):34.
pubmed: 35536143
doi: 10.1097/JU.0000000000002756
McKernan LC, Bonnet KR, Finn MTM, Williams DA, Bruehl S, Reynolds WS, et al. Qualitative analysis of treatment needs in interstitial cystitis/bladder pain syndrome: Implications for intervention. Can J Pain. 2020;4(1):181–98.
pubmed: 33367196
doi: 10.1080/24740527.2020.1785854
Oh-oka H. Clinical Efficacy of 1-Year Intensive Systematic Dietary Manipulation as Complementary and Alternative Medicine Therapies on Female Patients With Interstitial Cystitis/Bladder Pain Syndrome. Urology. 2017;1(106):50–4.
doi: 10.1016/j.urology.2017.02.053
Yu WR, Jhang JF, Chen BY, Ou SR, Li HM, Kuo HC. Multimodal Treatment with Cognitive Behavioral Therapeutic Intervention Plus Bladder Treatment Is More Effective than Monotherapy for Patients with Interstitial Cystitis/Bladder Pain Syndrome—A Randomized Clinical Trial. J Clin Med. 2022;11(20):6221.
pubmed: 36294541
doi: 10.3390/jcm11206221
FitzGerald MP, Payne CK, Lukacz ES, Yang CC, Peters KM, Chai TC, et al. Randomized Multicenter Clinical Trial of Myofascial Physical Therapy in Women With Interstitial Cystitis/Painful Bladder Syndrome and Pelvic Floor Tenderness. J Urol. 2012;187(6):2113–8.
pubmed: 22503015
doi: 10.1016/j.juro.2012.01.123
Borrego-Jimenez PS, Flores-Fraile J, Padilla-Fernández BY, Valverde-Martinez S, Gómez-Prieto A, Márquez-Sánchez MT, et al. Improvement in Quality of Life with Pelvic Floor Muscle Training and Biofeedback in Patients with Painful Bladder Syndrome/Interstitial Cystitis. J Clin Med. 2021;10(4):862.
pubmed: 33669734
doi: 10.3390/jcm10040862
Sönmez MG, Kozanhan B. Complete response to acupuncture therapy in female patients with refractory interstitial cystitis/bladder pain syndrome. Ginekol Pol. 2017;88(2):61–7.
pubmed: 28326514
doi: 10.5603/GP.a2017.0013
Lv TT, Lv JW, Wang SY, Jiang C, Gu YJ, Liu HR. Efficacy of electroacupuncture nerve stimulation therapy for interstitial cystitis/bladder pain syndrome. Zhongguo Zhen Jiu Chin Acupunct Moxibustion. 2019;39(5):467–72.
Bresler L, Westbay LC, Hekman L, Joyce C, Fitzgerald CM. Acupuncture for female bladder pain syndrome: a randomized controlled trial. Can J Urol. 2022;29(3):11154–61.
pubmed: 35691037
Chen W, Xie D, Liu G, Chen Y, Cai Z. Effect of Low-Dose Amitriptyline Treatment for Interstitial Cystitis/Bladder Pain Syndrome. Clin Res Urol. 2018;1(1):1–5.
Abat D, Altunkol A, Gökalp F. The effect of intravesical cocktail therapy combined with low-dose amitriptyline on primary bladder pain syndrome. Int Urogynecology J. 2022;33(5):1225–30.
doi: 10.1007/s00192-021-05043-y
Hanno P, Cervigni M, Choo MS, Clemens JQ, Lee MH, Malde S, et al. Summary of the 2023 report of the international consultation on incontinence interstitial cystitis/bladder pain syndrome (IC/BPS) committee. Continence. 2023;1(8):101056.
doi: 10.1016/j.cont.2023.101056
Thilagarajah R, Witherow RO, Walker MM. Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. BJU Int. 2001;87(3):207–12.
pubmed: 11167643
doi: 10.1046/j.1464-410x.2001.02031.x
Theoharides TC. Hydroxyzine in the treatment of interstitial cystitis. Urol Clin North Am. 1994;21(1):113–9.
pubmed: 8284834
doi: 10.1016/S0094-0143(21)00600-5
Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, et al. A Pilot Clinical Trial of Oral Pentosan Polysulfate And Oral Hydroxyzine in Patients With Interstitial Cystitis. J Urol. 2003;170(3):810–5.
pubmed: 12913705
doi: 10.1097/01.ju.0000083020.06212.3d
Ii RBH, Iii PHM, Paul D, Dooley TP. Treatment and Maintenance of Interstitial Cystitis/Bladder Pain Syndrome in Female Patients with Cetirizine-Famotidine: A Case Series. Case Rep Clin Med. 2023;12(2):61–71.
doi: 10.4236/crcm.2023.122009
Hanif AM, Armenti ST, Taylor SC, Shah RA, Igelman AD, Jayasundera KT, et al. Phenotypic Spectrum of Pentosan Polysulfate Sodium-Associated Maculopathy: A Multicenter Study. JAMA Ophthalmol. 2019;137(11):1275–82.
pubmed: 31486843
doi: 10.1001/jamaophthalmol.2019.3392
van Ophoven A, Vonde K, Koch W, Auerbach G, Maag KP. Efficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome: results of a systematic review of randomized controlled trials. Curr Med Res Opin. 2019;35(9):1495–503.
pubmed: 30849922
doi: 10.1080/03007995.2019.1586401
Desjarlais EB, Medic V, Kim JE. Incidence and Risk of Retinopathy in Patients With and Without Interstitial Cystitis and Pentosan Polysulfate Sodium Use. J Vitreoretin Dis. 2023;7(5):412–9.
pubmed: 37706083
doi: 10.1177/24741264231190978
Abreu-Mendes P, Dias N, Simães J, Dinis P, Cruz F, Pinto R. Daily low dose of tadalafil improves pain and frequency in bladder pain syndrome/interstitial cystitis patients. Turk J Urol. 2022;48(1):82–7.
doi: 10.5152/tud.2022.21292
Murina F, Graziottin A, Felice R, Gambini D. Alpha Lipoic Acid Plus Omega-3 Fatty Acids for Vestibulodynia Associated With Painful Bladder Syndrome. J Obstet Gynaecol Can. 2017;39(3):131–7.
pubmed: 28343553
doi: 10.1016/j.jogc.2016.12.035
Yoshimura N, Homma Y, Tomoe H, Otsuka A, Kitta T, Masumori N, et al. Efficacy and safety of intravesical instillation of KRP-116D (50% dimethyl sulfoxide solution) for interstitial cystitis/bladder pain syndrome in Japanese patients: A multicenter, randomized, double-blind, placebo-controlled, clinical study. Int J Urol. 2021;28(5):545–53.
pubmed: 33580603
doi: 10.1111/iju.14505
Moss NP, Chill HH, Sand PK, Chang C, Goldberg RP, Gafni-Kane A. A prospective, randomized trial comparing intravesical dimethyl sulfoxide (DMSO) to bupivacaine, triamcinolone, and heparin (BTH), for newly diagnosed interstitial cystitis/painful bladder syndrome (IC/PBS). Neurourol Urodyn. 2023;42(3):615–22.
pubmed: 36747494
doi: 10.1002/nau.25142
Sogutdelen E, Citamak B. Efficacy of intravesical cocktail therapy with or without dimethyl sulphoxide in interstitial cystitis. Cent Eur J Urol. 2022;75(3):299–304.
Nickel JC, Moldwin R, Lee S, Davis EL, Henry RA, Wyllie MG. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009;103(7):910–8.
pubmed: 19021619
doi: 10.1111/j.1464-410X.2008.08162.x
Evans R, Kohan A, Moldwin R, Radecki D, Geib T, Peters KM. Safety, tolerability, and efficacy of LiRIS 400 mg in women with interstitial cystitis/bladder pain syndrome with or without Hunner lesions. Neurourol Urodyn. 2021;40(7):1730–9.
pubmed: 34288094
doi: 10.1002/nau.24702
Raisin G, Dothan D, Perez D, Ala-Adin N, Kafka I, Shenfeld O, et al. Open Label, Pilot Evaluation of the Safety and Efficacy of Intravesical Sustained Release System of Lidocaine and Oxybutynin (TRG-100) for Patients With Interstitial Cystitis/Bladder Pain Syndrome, Overactive Bladder and Patients With Retained Ureteral Stents Following Endourological Interventions. Urology. 2023;178:42–7.
pubmed: 37268171
doi: 10.1016/j.urology.2023.05.016
Özkıdık M. Assessment of long-term intravesical hyaluronic acid, chondroitin sulfate and combination therapy for patients with bladder pain syndrome. Cent Eur J Urol. 2019;72(3):270–5.
Cervigni M, Sommariva M, Tenaglia R, Porru D, Ostardo E, Giammò A, et al. A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2017;36(4):1178–86.
pubmed: 27654012
doi: 10.1002/nau.23091
Banakhar MA. Comparative effectiveness and safety of cocktail therapy versus combined sodium hyaluronate and chondroitin sulphate (Ialuril): Intravesical instillation treatment of interstitial cystitis/bladder pain syndrome, which one to use? J Clin Urol. 2023;16(5):497–505.
doi: 10.1177/20514158211073449
Pinto RA, Costa D, Morgado A, Pereira P, Charrua A, Silva J, et al. Intratrigonal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind. Placebo Controlled Trial J Urol. 2018;199(4):998–1003.
pubmed: 29031769
Abreu-Mendes P, Ferrão-Mendes A, Botelho F, Cruz F, Pinto R. Effect of Intratrigonal Botulinum Toxin in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Long-Term, Single-Center Study in Real-Life Conditions. Toxins. 2022;14(11):775.
pubmed: 36356025
doi: 10.3390/toxins14110775
Yu WR, Jiang YH, Jhang JF, Chang WC, Kuo HC. Treatment Outcomes of Intravesical Botulinum Toxin A Injections on Patients with Interstitial Cystitis/Bladder Pain Syndrome. Toxins. 2022;14(12):871.
pubmed: 36548768
doi: 10.3390/toxins14120871
Kirk PS, Santiago-Lastra Y, Qin Y, Stoffel JT, Clemens JQ, Cameron AP. The effects of cystoscopy and hydrodistention on symptoms and bladder capacity in interstitial cystitis/bladder pain syndrome. Neurourol Urodyn. 2018;37(6):2002–7.
pubmed: 29566264
doi: 10.1002/nau.23555
Sandberg M, Whitman W, Bercu C, Rong A, Robusto B, Badlani G, et al. Pd05-10 longitudinal analysis of repeat hydrodistension in interstitial cystitis/bladder pain syndrome patients. J Urol. 2023;209(Supplement 4):e152.
doi: 10.1097/JU.0000000000003229.10
Walker SJ, Plair A, Hemal K, Langefeld CD, Matthews C, Badlani G, et al. Bladder Hydrodistention Does Not Result In a Significant Change In Bladder Capacity For Interstitial Cystitis/Bladder Pain Syndrome Patients. Urology. 2019;132:81–6.
pubmed: 31299328
doi: 10.1016/j.urology.2019.06.031
Zhang P, Wang JY, Zhang Y, Liao L, Lv JW, Ling Q, et al. Results of Sacral Neuromodulation Therapy for Urinary Voiding Dysfunction: Five-Year Experience of a Retrospective, Multicenter Study in China. Neuromodulation J Int Neuromodulation Soc. 2019;22(6):730–7.
doi: 10.1111/ner.12902
Gracely A, Cameron AP. Managing Interstitial Cystitis/Bladder Pain Syndrome in Older Adults. Drugs Aging. 2021;38(1):1–16.
pubmed: 33094445
doi: 10.1007/s40266-020-00810-w
Crescenze IM, Gupta P, Adams G, Oldendorf A, Stoffel JT, Romo PGB, et al. Advanced Management of Patients With Ulcerative Interstitial Cystitis/Bladder Pain Syndrome. Urology. 2019;1(133):78–83.
doi: 10.1016/j.urology.2019.07.036
Lai HH, Newcomb C, Harte S, Appleby D, Ackerman AL, Anger JT, et al. Comparison of deep phenotyping features of UCPPS with and without Hunner lesion: A MAPP-II Research Network Study. Neurourol Urodyn. 2021;40(3):810–8.
pubmed: 33604963
doi: 10.1002/nau.24623
van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7.
pubmed: 17900797
doi: 10.1016/j.eururo.2007.09.019
Ronstrom C, Lai HH. Presenting an atlas of Hunner lesions in interstitial cystitis which can be identified with office cystoscopy. Neurourol Urodyn. 2020;39(8):2394–400.
pubmed: 32902893
doi: 10.1002/nau.24500
Chennamsetty A, Khourdaji I, Goike J, Killinger KA, Girdler B, Peters KM. Electrosurgical management of Hunner ulcers in a referral center’s interstitial cystitis population. Urology. 2015;85(1):74–8.
pubmed: 25440759
doi: 10.1016/j.urology.2014.09.012
Otsuka A, Suzuki T, Aki R, Matsushita Y, Tamura K, Motoyama D, et al. Clinical characteristics of self-reported nocturia in patients with interstitial cystitis, and effects of bladder hydrodistention (with fulguration of Hunner lesions) on nocturia. Low Urin Tract Symptoms. 2019;11(2):O141–6.
pubmed: 30010251
Hillelsohn JH, Rais-Bahrami S, Friedlander JI, Okhunov Z, Kashan M, Rosen L, et al. Fulguration for Hunner ulcers: long-term clinical outcomes. J Urol. 2012;188(6):2238–41.
pubmed: 23083651
doi: 10.1016/j.juro.2012.08.013
Ko KJ, Cho WJ, Lee YS, Choi J, Byun HJ, Lee KS. Comparison of the Efficacy Between Transurethral Coagulation and Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients: A Prospective Randomized Controlled Trial. Eur Urol. 2020;77(5):644–51.
pubmed: 31959549
doi: 10.1016/j.eururo.2020.01.002
Ko KJ, Chung H, Suh YS, Lee SW, Kim TH, Lee KS. Therapeutic effects of endoscopic ablation in patients with Hunner type interstitial cystitis. BJU Int. 2018;121(4):659–66.
pubmed: 29232035
doi: 10.1111/bju.14097
Furuta A, Suzuki Y, Igarashi T, Kimura T, Egawa S, Yoshimura N. Reduction of Bladder Capacity Under Anesthesia Following Multiple Recurrences and Repeated Surgeries of Hunner Lesions in Patients With Interstitial Cystitis. Int Neurourol J. 2022;26(1):45–51.
pubmed: 35368185
doi: 10.5213/inj.2142102.051
Payne RA, O’Connor RC, Kressin M, Guralnick ML. Endoscopic ablation of Hunner’s lesions in interstitial cystitis patients. Can Urol Assoc J J Assoc Urol Can. 2009;3(6):473–7.
doi: 10.5489/cuaj.1178
Lee SW, Kim WB, Lee KW, Kim JM, Kim JH, Moon JE, et al. Long-term outcomes of ulcerative interstitial cystitis after complete transurethral resection with therapeutic hydrodistention. Int Urol Nephrol. 2021;53(2):219–27.
pubmed: 32926313
doi: 10.1007/s11255-020-02637-1
Shanberg AM, Malloy T. Treatment of interstitial cystitis with neodymium:YAG laser. Urology. 1987;29(4 Suppl):31–3.
pubmed: 3564231
Tomoe H, Yamashita K. Does repeated hydrodistension with transurethral fulguration for interstitial cystitis with Hunner’s lesion cause bladder contraction? Arab J Urol. 2019;17(1):77–81.
pubmed: 31258947
doi: 10.1080/2090598X.2019.1589753
Maeda D, Akiyama Y, Morikawa T, Kunita A, Ota Y, Katoh H, et al. Hunner-Type (Classic) Interstitial Cystitis: A Distinct Inflammatory Disorder Characterized by Pancystitis, with Frequent Expansion of Clonal B-Cells and Epithelial Denudation. PLoS ONE. 2015;10(11):e0143316.
pubmed: 26587589
doi: 10.1371/journal.pone.0143316
Jiang T, Zhou X, Chen Z, Xiong T, Fu J, Liu Z, et al. Clinical efficacy of submucosal injection of triamcinolone acetonide in the treatment of type II/III interstitial cystitis/bladder pain syndrome. BMC Urol. 2020;20(1):36.
pubmed: 32228552
doi: 10.1186/s12894-020-00597-3
Cox M, Klutke JJ, Klutke CG. Assessment of patient outcomes following submucosal injection of triamcinolone for treatment of Hunner’s ulcer subtype interstitial cystitis. Can J Urol. 2009;16(2):4536–40.
pubmed: 19364425
Mateu L, Izquierdo L, Franco A, Costa M, Lawrentschuk N, Alcaraz A. Pain relief after triamcinolone infiltration in patients with bladder pain syndrome with Hunner’s ulcers. Int Urogynecology J. 2017;28(7):1027–31.
doi: 10.1007/s00192-016-3213-3
Crescenze IM, Tucky B, Li J, Moore C, Shoskes DA. Efficacy, Side Effects, and Monitoring of Oral Cyclosporine in Interstitial Cystitis-Bladder Pain Syndrome. Urology. 2017;107:49–54.
pubmed: 28528859
doi: 10.1016/j.urology.2017.05.016
Forrest JB, Payne CK, Erickson DR. Cyclosporine A for refractory interstitial cystitis/bladder pain syndrome: experience of 3 tertiary centers. J Urol. 2012;188(4):1186–91.
pubmed: 22901569
doi: 10.1016/j.juro.2012.06.023
Brière R, Bouchard F, Ismail S, Gareau Labelle AK, Tu LM. A pilot study on oral cyclosporine A in association with fulguration for the treatment of interstitial cystitis with Hunner’s lesions. Neurourol Urodyn. 2022;41(6):1498–504.
pubmed: 35731015
doi: 10.1002/nau.24997
Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol. 2004;171(6 Pt 1):2138–41.
pubmed: 15126772
doi: 10.1097/01.ju.0000125139.91203.7a
Vollstedt A, Tennyson L, Turner K, Hasenau D, Saon M, McCartney T, et al. Evidence for Early Cyclosporine Treatment for Hunner Lesion Interstitial Cystitis. Female Pelvic Med Reconstr Surg. 2022;28(1):e1-5.
pubmed: 34608034
doi: 10.1097/SPV.0000000000001108
Linn JF, Hohenfellner M, Roth S, Dahms SE, Stein R, Hertle L, et al. Treatment of interstitial cystitis: comparison of subtrigonal and supratrigonal cystectomy combined with orthotopic bladder substitution. J Urol. 1998;159(3):774–8.
pubmed: 9474146
doi: 10.1016/S0022-5347(01)63726-1
Andersen AV, Granlund P, Schultz A, Talseth T, Hedlund H, Frich L. Long-term experience with surgical treatment of selected patients with bladder pain syndrome/interstitial cystitis. Scand J Urol Nephrol. 2012;46(4):284–9.
pubmed: 22452583
doi: 10.3109/00365599.2012.669789
Peeker R, Aldenborg F, Fall M. The treatment of interstitial cystitis with supratrigonal cystectomy and ileocystoplasty: difference in outcome between classic and nonulcer disease. J Urol. 1998;159(5):1479–82.
pubmed: 9554337
doi: 10.1097/00005392-199805000-00018
Redmond EJ, Flood HD. The role of reconstructive surgery in patients with end-stage interstitial cystitis/bladder pain syndrome: is cystectomy necessary? Int Urogynecology J. 2017;28(10):1551–6.
doi: 10.1007/s00192-017-3307-6
Brandt SB, Kirkeby HJ, Brandt ASV, Jensen JB. Urinary diversion in the treatment of refractory bladder pain syndrome. Scand J Urol. 2019;53(6):424–30.
pubmed: 31407934
doi: 10.1080/21681805.2019.1649720
Akiyama Y, Niimi A, Igawa Y, Nomiya A, Yamada Y, Sato Y, et al. Cystectomy for patients with Hunner-type interstitial cystitis at a tertiary referral center in Japan. Low Urin Tract Symptoms. 2022;14(2):102–8.
pubmed: 34704374
doi: 10.1111/luts.12416
Rössberger J, Fall M, Jonsson O, Peeker R. Long-term results of reconstructive surgery in patients with bladder pain syndrome/interstitial cystitis: subtyping is imperative. Urology. 2007;70(4):638–42.
pubmed: 17991529
doi: 10.1016/j.urology.2007.05.028
Teegavarapu PS, Sahai A, Chandra A, Dasgupta P, Khan MS. Eosinophilic cystitis and its management. Int J Clin Pract. 2005;59(3):356–60.
pubmed: 15857336
doi: 10.1111/j.1742-1241.2004.00421.x
Mosholt KSS, Dahl C, Azawi NH. Eosinophilic cystitis: three cases, and a review over 10 years. BMJ Case Rep. 2014;2014:bcr2014205708.
pubmed: 25312971
doi: 10.1136/bcr-2014-205708
van den Ouden D. Diagnosis and management of eosinophilic cystitis: a pooled analysis of 135 cases. Eur Urol. 2000;37(4):386–94.
pubmed: 10765067
doi: 10.1159/000020183
Schmitz-Dräger BJ, Skutetzki A, Rieker RJ, Schwab SA, Stöhr R, Bismarck E, et al. Eosinophilic cystitis mimicking bladder cancer-considerations on the management based upon a case report and a review of the literature. Virchows Arch Int J Pathol. 2021;479(3):523–7.
doi: 10.1007/s00428-021-03049-x
Simonato FA, Pavan N, Pinelli M, Tulone G, Giaimo R, Martorana A, et al. A conservative treatment for eosinophilic cystitis. IJU Case Rep. 2023;6(1):8–12.
pubmed: 36605690
doi: 10.1002/iju5.12533
Kurdi MS, Theerth KA, Deva RS. Ketamine: Current applications in anesthesia, pain, and critical care. Anesth Essays Res. 2014;8(3):283–90.
pubmed: 25886322
doi: 10.4103/0259-1162.143110
Li CC, Wu ST, Cha TL, Sun GH, Yu DS, Meng E. A survey for ketamine abuse and its relation to the lower urinary tract symptoms in Taiwan. Sci Rep. 2019;9(1):7240.
pubmed: 31076629
doi: 10.1038/s41598-019-43746-x
Winstock AR, Mitcheson L, Gillatt DA, Cottrell AM. The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int. 2012;110(11):1762–6.
pubmed: 22416998
doi: 10.1111/j.1464-410X.2012.11028.x
Lee WC, Su CH, Tain YL, Tsai CN, Yu CC, Chuang YC. Potential Orphan Drug Therapy of Intravesical Liposomal Onabotulinumtoxin-A for Ketamine-Induced Cystitis by Mucosal Protection and Anti-inflammation in a Rat Model. Sci Rep. 2018;8(1):5795.
pubmed: 29643467
doi: 10.1038/s41598-018-24239-9
Mason K, Cottrell AM, Corrigan AG, Gillatt DA, Mitchelmore AE. Ketamine-associated lower urinary tract destruction: a new radiological challenge. Clin Radiol. 2010;65(10):795–800.
pubmed: 20797465
doi: 10.1016/j.crad.2010.05.003
Lin CC, Lin ATL, Yang AH, Chen KK. Microvascular Injury in Ketamine-Induced Bladder Dysfunction. PLoS ONE. 2016;11(8):e0160578.
pubmed: 27529746
doi: 10.1371/journal.pone.0160578
Wu P, Wang Q, Huang Z, Wang J, Wu Q, Lin T. Clinical staging of ketamine-associated urinary dysfunction: a strategy for assessment and treatment. World J Urol. 2016;34(9):1329–36.
pubmed: 26803767
doi: 10.1007/s00345-016-1759-9
Ou YL, Liu CY, Cha TL, Wu ST, Tsao CW. Complete reversal of the clinical symptoms and image morphology of ketamine cystitis after intravesical hyaluronic acid instillation: A case report. Medicine (Baltimore). 2018;97(28):e11500.
pubmed: 29995815
doi: 10.1097/MD.0000000000011500
Yee CH, Lai PT, Lee WM, Tam YH, Ng CF. Clinical Outcome of a Prospective Case Series of Patients With Ketamine Cystitis Who Underwent Standardized Treatment Protocol. Urology. 2015;86(2):236–43.
pubmed: 26199162
doi: 10.1016/j.urology.2015.05.003
Jhang JF, Kuo HC. Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection. Toxins. 2015;7(6):2232–50.
pubmed: 26094697
doi: 10.3390/toxins7062232
Lee YK, Jhang JF, Kuo HC. Clinical Outcome of Augmentation Enterocystoplasty for Patients with Ketamine-induced Cystitis. Pain Physician. 2017;20(3):E431–6.
pubmed: 28339443